Tag Archives: SYRS

H.C. Wainwright Maintains a Hold Rating on Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $5.02, close to its 52-week low of $4.88. According

Syros Pharmaceuticals (SYRS) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today. The company’s shares closed last Monday at $5.01, close to its 52-week low of $4.88. According to TipRanks.com, Nadeau is a 4-star

Syros Pharmaceuticals (SYRS) Gets a Buy Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report). The company’s shares closed last Monday at $5.40, close to its 52-week low of $5.17. According to TipRanks.com,

Syros Pharmaceuticals (SYRS) Gets a Hold Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $10. The company’s shares closed yesterday at $7.17. Fein wrote: “Our price target of

H.C. Wainwright Remains a Hold on Syros Pharmaceuticals (SYRS)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $10. The company’s shares closed yesterday at $6.90. Fein commented: “Our price target of

Roth Capital Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)

Roth Capital analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $6.81, close to its 52-week low of $6.25. Marango